Ravimiamet

What Ravimiamet does

Ravimiamet (State Agency of Medicines) is the Estonian governmental regulatory authority for medicines, operating under the Ministry of Social Affairs. Established in its current form in 1993 (with predecessor Estonian Centre on Medicines founded in 1991), the agency is responsible for the protection and promotion of public and animal health through supervision of medicines for human and veterinary use. It oversees drug marketing authorization, activity licensing for pharmacies, distributors, and manufacturers, pharmacovigilance, clinical trial oversight, medical device regulation, and narcotics control within Estonia. Ravimiamet employs over 90 staff across 6 departments, headquartered in Tartu with a secondary office in Tallinn, and serves healthcare providers, pharmacies, distributors, pharmaceutical manufacturers, medical device companies, veterinary stakeholders, and the Estonian public.

The agency operates a portfolio of digital regulatory infrastructure including the Ravimiregister (national Drug Register containing all authorized medicines with pricing and reimbursement data), the Kliendiportaal (Client Portal) for electronic licensing and authorization applications, the Tegevuslubade register (Activity Licenses Register), the Apteekide kaart (Pharmacy Map), the INNA surveillance information system, and the MSA Medical Devices and Appliances Database, which was relaunched in July 2026. These systems provide self-service e-government functionality for mandatory regulatory interactions and constitute the agency's core technological surface. Ravimiamet is integrated into the EU regulatory network, collaborating with the European Medicines Agency (EMA), Heads of Medicines Agencies (HMA), the European Directorate for the Quality of Medicines (EDQM), and the European Commission, alongside international coordination with WHO, the FDA, and UN agencies.

The agency's revenue model is based on state fees for licensing, authorization, and registration services as defined by Estonian law, supplemented by public budget allocation as a government agency. It does not sell products and does not publish revenue figures. Distribution of services occurs exclusively through digital e-services portals and physical office locations within Estonia. There is no private ownership, no equity financing, no M&A activity, and no commercial go-to-market motion; the entity is a state-owned regulator with statutory monopoly over its domain.

Name

Ravimiamet

Legal name

Ravimiamet

Website

https://ravimiamet.ee

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

51–100 employees

Short description

Ravimiamet is Estonia's governmental State Agency of Medicines, regulating human and veterinary drugs, pharmacies, manufacturers, and medical devices through licensing, pharmacovigilance, and national digital registries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulation

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615)

SIC

Services-Health Services (8000)

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industries

Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI), Medical Device Regulators (HLAJADAC), Controlled Substances & Narcotics Regulators (HLAJADAK), Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Pharmaceutical regulation
• Drug registration
• Pharmacovigilance services
• Medical device oversight
• Veterinary medicine licensing

Headquarters

HQ city

Tartu

HQ country

Estonia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. State Fees (Riigilõivud): Governmental regulatory agency funded through state fees for licensing, authorization, and registration services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Ravimiamet (State Agency of Medicines) is Estonia's governmental regulatory authority for medicines, operating under the Ministry of Social Affairs. The agency supervises medicines for human and veterinary use, granting marketing authorizations, issuing activity licenses for pharmacies and manufacturers, monitoring pharmacovigilance and adverse drug reactions, and maintaining the national drug register (Ravimiregister) and medical devices database. Its core outputs are regulatory approvals, licenses, surveillance activities, and the public registries that document the Estonian pharmaceutical market.

Product overview

Ravimiamet (State Agency of Medicines) is Estonia's governmental regulatory body under the Ministry of Social Affairs responsible for protecting and promoting public and animal health through the supervision of medicines for human and veterinary use. The agency operates a portfolio of electronic services and registries including the Ravimiregister (Drug Register) for medicines on the Estonian market, the Meditsiiniseadmete andmekogu (Medical Devices Database), the Kliendiportaal (Client Portal) for electronic applications, the Tegevuslubade register (Activity Licenses Register), and the Apteekide kaart (Pharmacy Map). The agency also maintains access to EU-level centralized registers for clinical trials and centrally authorized medicines.

Differentiator

Problem solved

Functional benefit

Products and services

• Ravimiregister (Drug Register) National register providing public access to information on all medicines with marketing authorization in Estonia, including drug characteristics, pricing, reimbursement status, and package codes. Used by healthcare professionals, patients, pharmacies, and manufacturers for transparency and lookup.
• Kliendiportaal (Client Portal) Authenticated electronic portal that enables pharmaceutical companies and other applicants to submit and manage applications for marketing authorizations, activity licenses, and other regulatory processes with Ravimiamet.
• Tegevuslubade register (Activity Licences Register) Public register of activity licenses granted to pharmacies, wholesale distributors, and manufacturers for the handling of medicines in Estonia, supporting license lookup and verification of legal operation.
• Apteekide kaart (Pharmacy Map) Public lookup tool that helps citizens locate licensed pharmacies across Estonia, supporting access to dispensing services and information.
• INNA Information System Information system used by Ravimiamet for the surveillance and monitoring of medicines, supporting pharmacovigilance and adverse drug reaction reporting.
• Meditsiiniseadmete ja abivahendite andmekogu (MSA - Medical Devices and Appliances Database) Database for the collection, management, and publication of data on medical devices and appliances on the Estonian market, supporting medical device registration, market surveillance, and adverse event reporting.

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

15 partnerships are on record, tiered core and minor.

• European Medicines Agency (EMA)coreStrategic or Co-development PartnerRavimiamet collaborates with EMA on centrally authorized medicines, safety monitoring, and regulatory harmonization within the EU. The agency references EMA databases and guidelines for drug authorization standards.
• European Commission / HealthcoreStrategic or Co-development PartnerOperates under the regulatory framework of the European Commission for health-related pharmaceutical legislation and market surveillance.
• World Health Organisation Essential Drugs and Medicines Policy (WHO-EDM)minorStrategic or Co-development PartnerCollaborates with WHO on essential medicines policies and global health standards for drug regulation.
• Heads of Medicines Agencies (HMA)coreStrategic or Co-development PartnerMember of the HMA network connecting European national medicines regulatory authorities for information sharing and regulatory harmonization.
• European Directorate for the Quality of Medicines (EDQM)coreStrategic or Co-development PartnerWorks with EDQM on European Pharmacopoeia standards and quality standards for medicines in Europe.
• US Food and Drug Administration (FDA)minorStrategic or Co-development PartnerInternational regulatory cooperation with FDA on drug safety, standards, and best practices.
• International Narcotics Control BoardminorStrategic or Co-development PartnerCollaboration on control of narcotic drugs and psychotropic substances under international conventions.
• United Nations Office on Drugs and CrimeminorStrategic or Co-development PartnerInternational cooperation on drug control and prevention of drug abuse.
• Ministry of Social Affairs (Sotsiaalministeerium)coreOthersRavimiamet operates as an agency under the Ministry of Social Affairs, which provides oversight and policy direction for the agency's activities.
• Health Insurance Fund (Tervisekassa)coreOthersCollaboration on drug reimbursement, pricing, and reimbursement lists for medicines covered by health insurance.
• Health Board (Terviseamet)coreOthersCoordination on public health matters, infectious disease control, and health-related regulations.
• Consumer Authority and Technical Regulatory Authority (TTJA)minorOthersCoordination on consumer protection matters related to medical products and devices.
• Agriculture and Food Board (Põllumajandus- ja Toiduamet)minorOthersCoordination on matters where product classification overlaps between medicines and other regulated products.
• Tax and Customs Board (Maksu- ja Tolliamet)minorOthersCollaboration on customs matters related to import and export of medicines and controlled substances.
• University of TartuminorStrategic or Co-development PartnerAcademic collaboration on pharmaceutical research, clinical trials, and professional education.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• U.S. Food and Drug Administration (FDA): U.S. federal regulator covering drug and medical-device authorization, pharmacovigilance, and supply-chain oversight. Ravimiamet has an active cooperation agreement with the FDA on drug safety and standards.
• European Medicines Agency (EMA): EU-level medicines regulator that Ravimiamet actively collaborates with on centralized authorizations, safety monitoring, and harmonization. EMA is the supranational authority above national agencies like Ravimiamet.
• BfArM (Federal Institute for Drugs and Medical Devices, Germany): Large EU national regulator with broad portfolio across medicines, medical devices, and pharmacovigilance. Comparable function to Ravimiamet but at far greater scale and complexity.
• MHRA (UK Medicines and Healthcare products Regulatory Agency): UK national regulator with comprehensive scope across pharmaceuticals, medical devices, and blood products. Comparable functional mandate to Ravimiamet but operating in a much larger market.

Direct peers

• Fimea (Finnish Medicines Agency): Finnish national medicines regulator covering marketing authorization, pharmacovigilance, and pharmaceutical supply-chain oversight. Closest geographic and functional peer to Ravimiamet among Nordic-Baltic agencies.
• VVKT (State Medicines Control Agency of Lithuania): Lithuanian national medicines regulator with parallel responsibilities for human and veterinary drug authorization, market surveillance, and pharmaceutical licensing. Direct Baltic peer to Ravimiamet.
• Swedish Medical Products Agency (Läkemedelsverket): Swedish national regulator responsible for medicines and medical devices, with similar scope to Ravimiamet but materially larger scale and broader international work-sharing role.
• Zāļu valsts aģentūra (State Agency of Medicines of Latvia): Latvian national medicines regulator performing the same core functions as Ravimiamet (marketing authorization, pharmacovigilance, licensing) within the Baltic region. Closest peer in scope and market size.

Others

• European Directorate for the Quality of Medicines (EDQM): Council of Europe body that sets European Pharmacopoeia standards. Ravimiamet partners with EDQM for quality standards for medicines; functions as an upstream standards-setter rather than direct competitor.
• Heads of Medicines Agencies (HMA): Network of European national medicines regulatory authorities of which Ravimiamet is a member. HMA coordinates regulatory harmonization and information sharing among EU member-state agencies, providing the framework for Ravimiamet's cross-border work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ravimiamet-state-agency-of-medicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ravimiamet